Gabapentin - Revision history

MDElliottMD: parser-claude: Gabapentin MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:22:53Z

parser-claude: Gabapentin MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:22, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Gabapentin		\| generic = Gabapentin
	\| brand = Neurontin		\| brand = Neurontin (IR), Gralise (ER), Horizant (gabapentin enacarbil ER)
	\| structure =		\| structure =
	\| classes = Gabapentinoid, Anticonvulsant		\| classes = [[:Category:Gabapentinoids\|Gabapentinoid]], [[:Category:Anticonvulsants\|Anticonvulsant]], [[:Category:Neuropathic pain medicines\|Neuropathic pain medicine]]
	\| ~~mechanism~~ = ~~Alpha~~-2-~~delta voltage~~-~~gated calcium channel ligand~~		\| uses = <vote slug="partial-seizures-adjunct-use">Partial-onset seizures (adjunctive, FDA)</vote>, <vote slug="postherpetic-neuralgia-use">Postherpetic neuralgia (FDA)</vote>, <vote slug="restless-legs-syndrome-use">Restless legs syndrome (Horizant, FDA)</vote>, <vote slug="neuropathic-pain-broad-use">Neuropathic pain (off-label, broad)</vote>, <vote slug="fibromyalgia-use">Fibromyalgia (off-label)</vote>, <vote slug="anxiety-gabapentin-use">Anxiety disorders (off-label, evidence mixed)</vote>, <vote slug="aud-gabapentin-use">Alcohol use disorder (off-label)</vote>, <vote slug="menopausal-hot-flashes-use">Menopausal hot flashes (off-label)</vote>
	\| ~~uses~~ =		\| starting_dose = 300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID
	\| ~~starting_dose~~ =		\| preparations = Capsules 100, 300, 400 mg; tablets 600, 800 mg; oral solution 250 mg/5 mL; Gralise ER tablets 300, 600 mg (once-daily); Horizant ER tablets 300, 600 mg (gabapentin enacarbil, an inactive parent compound metabolized to gabapentin in vivo)
	\| ~~preparations~~ =		\| fda_max = 3600 mg/day; off-label doses higher are common but bioavailability saturates well below this
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = 1-2 weeks for neuropathic pain and anxiolytic effect; anticonvulsant effect at therapeutic plasma level
	\| duration =		\| duration = TID dosing for IR; once-daily for ER formulations
	\| halflife =		\| halflife = 5-7 hours<ref name="neurontin-label">FDA Prescribing Information, Neurontin (gabapentin), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = '''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose<ref name="neurontin-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; some signal for cardiac malformations and developmental delay but confounded by maternal disease and polytherapy.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] federally in US. State-level scheduling: '''Schedule V''' in Kentucky, Tennessee, Virginia, North Dakota, Michigan, Alabama, Utah, Wyoming, North Carolina, Mississippi, Louisiana, Connecticut, Ohio (and growing), reflecting documented misuse and overdose-potentiation in combination with opioids<ref name="neurontin-label" />
	\| ~~intro~~ =		\| mechanism = <vote slug="gabapentin-mech-claim">Despite the name, gabapentin does '''not''' bind GABA receptors or affect GABA reuptake. It binds the α2δ-1 auxiliary subunit of voltage-gated calcium channels, reducing presynaptic Ca²⁺ influx and consequent release of excitatory neurotransmitters (glutamate, substance P, norepinephrine, calcitonin gene-related peptide). The pain and anticonvulsant effects share this presynaptic-excitability dampening mechanism.</vote> Saturable LAT-1 absorption is the dominant clinical-pharmacokinetic quirk and explains why dose increases above ~1800 mg/day yield diminishing plasma exposure. Horizant addresses this through the enacarbil parent compound, which is absorbed by non-saturable transporters and then metabolized to gabapentin in vivo<ref name="neurontin-label" />.
	\| pharmacokinetics =
	\| ~~pharmacodynamics~~ =
	\| ~~indications =~~
	~~\| dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	~~[[Category:GABAergics]]~~		== References ==
	[[Category:~~Sedative-hypnotics~~]]		<references />
	[[Category:~~Calcium channel blockers (T-type or N/P/Q-type)~~]]
	[[Category:~~Antiepileptics~~]]		[[Category:Gabapentinoids]]
			[[Category:Anticonvulsants]]
			[[Category:Neuropathic pain medicines]]

MDElliottMD: Category taxonomy ship: retag Anticonvulsants -> Antiepileptics, Sedative-Hypnotics -> Sedative-hypnotics

2026-05-22T00:36:39Z

Category taxonomy ship: retag Anticonvulsants -> Antiepileptics, Sedative-Hypnotics -> Sedative-hypnotics

← Older revision		Revision as of 00:36, 22 May 2026
Line 32:		Line 32:

	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-~~Hypnotics~~]]		[[Category:Sedative-hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:~~Anticonvulsants~~]]		[[Category:Antiepileptics]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

2026-05-19T18:00:14Z

Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 30:		Line 30:
	\| references =		\| references =
	}}		}}


	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants ~~/ Antiepileptics~~]]		[[Category:Anticonvulsants]]

MDElliottMD: Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

2026-05-18T00:48:05Z

Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

← Older revision		Revision as of 00:48, 18 May 2026
Line 32:		Line 32:


	~~[[Category:Psychostimulants]]~~
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:42Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 32:		Line 32:


	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:44:55Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:44, 17 May 2026
Line 32:		Line 32:


	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Comprehensive categorization: +Calcium channel blockers (T-type or N/P/Q-type), Anticonvulsants / Antiepileptics

2026-05-15T18:42:20Z

Comprehensive categorization: +Calcium channel blockers (T-type or N/P/Q-type), Anticonvulsants / Antiepileptics

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
			[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
			[[Category:Anticonvulsants / Antiepileptics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:58Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
			[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:53Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:35Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =